At Crinetics, we believe patient-focused drug development is vital. From molecule to medicine, we value the patient’s voice and encourage patient input into our clinical development programs and beyond. Learn more about our patient advocacy efforts: https://lnkd.in/gSUMgvpG
Crinetics Pharmaceuticals
Biotechnology Research
San Diego, California 17,821 followers
Discovering drugs for endocrine diseases and endocrine-related tumors. #acromegaly #crinetics #CarcinoidSyndrome
About us
This place is about more than a pharmaceutical career. It’s about making a real difference in the lives of patients. That’s why we’re here. That’s why you should maybe think about being here, too. Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels.
- Website
-
https://crinetics.com
External link for Crinetics Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2008
- Specialties
- Drug Discovery, Endocrinology, RareDisease, and Biotech
Locations
-
Primary
6055 Lusk Blvd
San Diego, California 92121, US
Employees at Crinetics Pharmaceuticals
Updates
-
Regular injections can be a painful part of managing acromegaly and can sometimes lead to uncomfortable reactions, making an already difficult journey even harder. Are you an #endocrinologist treating acromegaly? Learn more about how injection site pain may be impacting your patients: https://bit.ly/3WXRt4i
-
#CRNX announces second quarter 2024 earnings. Learn more: https://bit.ly/3WLaoOK
-
-
We are excited to announce the launch of ACRO/TRUTH, an educational initiative spotlighting the challenges faced by acromegaly patients managing their disease. This resource features authentic patient stories and data on injection site reactions, side effects, breakthrough symptoms, and the emotional impact of the current standard-of-care. ACRO/TRUTH is based on extensive interviews with patients, endocrinologists and leading patient organizations like Acromegaly Community. Learn more about this initiative: https://bit.ly/3YxHiEZ #AcromegalyAwareness #Endocrinology
-
Uncontrolled #acromegaly can have a debilitating impact on daily functioning and quality of life. Symptoms, such as fatigue and pain, are sometimes difficult to manage regularly. We’re focused on addressing this unmet need – and others – for people living with acromegaly. Learn more about our product candidate that we’re currently developing: https://bit.ly/4cTcdzP
-
For acromegaly patients on injectable somatostatin receptor ligands (SRLs), treatment-related symptoms and side effects can impair quality of life. Understanding the challenges people living with #acromegaly face is critical to improving their quality of life. Discover the truth about challenges faced by acromegaly patients: https://lnkd.in/gYgA7Kis
-
Endocrinology impacts almost every aspect of human health. Our world-class, in-house R&D organization continues to produce a deep pipeline of transformative novel molecules that are purposefully designed by harnessing our deep understanding of endocrine systems and patient burden, and with a committed and uncompromising pursuit of science and medicine. Learn more about our approach here: https://bit.ly/3W533dq
-
As part of our commitment to improving care for #endocrine diseases, we launched AcromegalyTruth.com. This platform features research and patient perspectives on the challenges of treating #acromegaly. Designed with healthcare professionals in mind, this site aims to deepen the understanding of the patient experience. Explore the site and discover the truth about acromegaly: https://bit.ly/4bhU25j
-
Congenital adrenal hyperplasia (CAH) is a rare endocrine disorder with significant unmet needs, impacting approximately 1 in 10,000 to 15,000 live births in the U.S. and Europe. Our Co-founder and Chief Scientific Officer, Stephen Betz, reflects on Crinetics' commitment to addressing the urgent needs of the CAH community. #CAHAwarenessMonth
-
“The privilege to come to work each day and collaborate with such a fantastic, creative, and motivated team knowing that we are all working so hard to help people is what excites and inspires me the most about working at Crinetics.” – Michael Johns, Senior Scientist 2, Drug Metabolism and Pharmacokinetics Meet Michael, this month's #EmployeeSpotlight: https://bit.ly/4ciR1Tg
-